Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOVX @ .07: Now @ 50DMA..... 200DMA is .08.
GeoVax has put together some of the most imporatnt names in vaccine in the last few weeks as they start the next round of human injections for their 100% effective AIDS vaccine.
GOVX is one of the very big plays going forward. Simple as that.
13-D.........Emory U @ 8.4% ownership.
http://ih.advfn.com/p.php?pid=nmona&article=73554614&symbol=GOVX
Website LINK:
https://www.geovax.com/
CRTN @ $1.05. Nasdaq compliance & big Q4 pending.
Up 120% since I posted it here but will go big from here.
One of the top Januray Effect plays.
CVM @ .08. Big vol now. Frost play moving assets in?
Picked some up just like I did BCDA when I head Frost was moving assets in
CVM , also has Phase 3 drugs
NOTE: 50/200 DMA is .08. Big tech indicator for GOVX
Looking great with big names coming on board and big companies taking positions in last week.
CRTN: Right there @ $1.00 door. Puts in Nas compliance.
10 days over $1.00
More news!. 13-D filed @ 5pm: Emory University owns 8.4%.
Link:
http://ih.advfn.com/p.php?pid=nmona&article=73554614&symbol=GOVX
NOTE: Earlier today a 13-G was filed related to ownership by Sabby.
GOVX: 13-D filed @ 5pm: Emory University owns 8.4%.
Link:
http://ih.advfn.com/p.php?pid=nmona&article=73554614&symbol=GOVX
NOTE: Earlier today a 13-G was filed related to ownership by Sabby.
GOVX: 13-G filed....
Getting interesting.
Link:
http://ih.advfn.com/p.php?pid=nmona&article=73552680&symbol=GOVX
GOVX....NEWS!....SABBY now owns 10%. Wow.
Form 13 just filed.
CRTN @ .95. Only profitable Nas play under $3. 6M float
CRTN going big in coming sessions as major positive Q4 report looms.
Big play. Traded over $5.50 last time in profit mode.
CRTN @ .95. Only profitable Nas play under $3. 6M float
CRTN going big in coming sessions as major positive Q4 report looms.
Big play. Traded over $5.50 last time in profit mode.
GOVX: Fed AIDS milestone $$ & Zika $$ due too!.
GeoVax market cap is $3.2M.
The money could easily be more than the ENTIRE compnay market cap.
Wild.
CVM @ .082: In on offering close & partial FDA hold being lifted (maybe).
Should rise nicely just on the recent stock closing.
A lift on the FDA partial hold and a big move on tap.
CVM is Phase 3 for head & neck cancer.
Based on my DD, the FDA Partial Hold will indeed be lifted.
Patients still being treated, etc.
Website:
http://www.cel-sci.com/
CVM @ .082: In on offering close & partial FDA hold being lifted (maybe).
Should rise nicely just on the recent stock closing.
A lift on the FDA partial hold and a big move on tap.
CVM is Phase 3 for head & neck cancer.
Based on my DD, the FDA Partial Hold will indeed be lifted.
Patients still being treated, etc.
Website:
http://www.cel-sci.com/
CRTN @ .90: watch for that $1.00 break. On way.
Looking very good on light volume.
$CRTN @ .80s: Only profitable Nasdaq play under $3.00. 6M float.
Turnaround play in profit now.
Strong profit Q4 news pending. Catalyst play in spades.
Was $5.50s last time in profit mode.
Website:
http://www.cartesian.com/
GOVX: Major players step on board as AIDS vax trial begins.
The new Chief Science Officer and the new Science Advisory Board are a whos who of vaccine science.
These folks are linking up with GeoVax because the know history is in the making and millions of lives may be saved.
Just astounding that GOVX is @ .06 cents now.
$3.2M market cap with Fed human AIDS vax funding news on deck.
Link:
https://www.geovax.com/component/easyblog/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html?Itemid=101
CRTN @ .80s: Nasdaq tech/media play. No bio/pharma blowup hazard.
Takes some cajones to hold some of those bio/pharma stocks.
Even a real good looker can drop 90% in a day.
The value of owning CRTN in that regard has not been mentioned, but it is key, imo.
Breaking over $1.00 will be big. Should bring on some big volume days and move nicely.
Website:
http://www.cartesian.com/
CJJD: 8-K out. Investor stake @ $2.20
No Company press release yet.
LINK:
http://archive.fast-edgar.com//20170104/AI29D22CL2224262222D22X25U8QZ2224292/
CJJD: 8-K out. Investor stake @ $2.20: RTQ=$1.85
No Company press release yet.
LINK:
http://archive.fast-edgar.com//20170104/AI29D22CL2224262222D22X25U8QZ2224292/
CJJD: 8-K out. Investor stake @ $2.20: RTQ=$1.85
No Company press release yet.
LINK:
http://archive.fast-edgar.com//20170104/AI29D22CL2224262222D22X25U8QZ2224292/
CRTN @ .87: Top January Effect play.
Q4 due week of 2/6/17.
Likely CRTN gets hotter as that date gets closer.
ONLY profitable Nasdaq company trading under $3.00 now.
See CEO interview @ link.
Link:
http://ir.cartesian.com/phoenix.zhtml?c=110509&p=irol-irhome
CRTN @ .87: Top January Effect play.
Q4 due week of 2/6/17.
Likely CRTN gets hotter as that date gets closer.
See CEO interview @ link.
Link:
http://ir.cartesian.com/phoenix.zhtml?c=110509&p=irol-irhome
GOVX @ .06: NLNK inventor of Ebola vax now GOVX Chairman
Dr. Thomas Monath developed and invented the 100% effective Ebola prevention vaccine that made so much big news two weeks ago for NLNK & partner Merck.
Now, GeoVax, GOVX @ .06, tiny 42M float, has brought Dr. Monath on board just as GOVX begins the next round of human vaccinations with the GOVX 100% effective AIDS vax.
Dr. Monath is a major figure in vaccine science.
In addition, the other scientists also brought on board are the biggest names in vaccine. Imo, the are about to make news in AIDS like they did with Ebola.
LINK:
https://www.geovax.com/component/easyblog/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html?Itemid=101
GOVX @ .06: NLNK inventor of Ebola vax now GOVX Chairman
Dr. Thomas Monath developed and invented the 100% effective Ebola prevention vaccine that made so much big news two weeks ago for NLNK & partner Merck.
Now, GeoVax, GOVX @ .06, tiny 42M float, has brought Dr. Monath on board just as GOVX begins the next round of human vaccinations with the GOVX 100% effective AIDS vax.
Dr. Monath is a major figure in vaccine science.
In addition, the other scientists also brought on board are the biggest names in vaccine. Imo, the are about to make news in AIDS like they did with Ebola.
LINK:
https://www.geovax.com/component/easyblog/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html?Itemid=101
MRK & NLNK ebola vax inventor now Chairman of tiny GOVX.
Looking likely that MRK or NLNK will buy out this tiny company.
Link:
https://finance.yahoo.com/news/geovax-announces-formation-scientific-advisory-140000691.html
NOTE: The person leading the development with Merck & NLNK is now a Chairman Of new GeoVax science board.. That is big.
"Thomas P. Monath, MD, (Chairman). Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck
NOTE 2: GeoVax has an AIDS vaccine that has been 100% effective in human trials. Another round of vaccinations starts this month.
MRK & NLNK ebola vax inventor now Chairman of tiny GOVX.
Looking likely that MRK or NLNK will buy out this tiny company.
Link:
https://finance.yahoo.com/news/geovax-announces-formation-scientific-advisory-140000691.html
NOTE: The person leading the development with Merck & NLNK is now a Director Of GeoVax. That is big.
"Thomas P. Monath, MD, (Chairman). Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck
NOTE 2: GeoVax has an AIDS vaccine that has been 100% effective in human trials. Another round of vaccinations starts this month.
Biggest names in vaccine science make news today.
Incredible news for anyone following the vaccine sector.
Link:
https://www.geovax.com/news-events/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html
GOVX: Biggest names in vaccine science named Directors today. Wild.
Take a look at the scientists named today, including the person that developed the 100% effective Ebola vaccine that made huge news last week for NLNK.
GOVX is @ .06, 42M share float.
NOTE: GOVX has a an AIDS prevention vaccine that is 100% effective in human trials so far.
Just an insane number.
Link:
https://www.geovax.com/news-events/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html
GOVX: Biggest names in vaccine science named Directors today.
Take a look at the scientists named today, including the person that developed the 100% effective Ebola vaccine that made huge news last week for NLNK.
GOVX is @ .06
Just an insane number.
Link:
https://www.geovax.com/news-events/entry/2017/01/03/geovax-announces-formation-of-scientific-advisory-board.html
NLNK: Developer of Ebola vax now GOVX Director.
GeoVax: GOVX @ .06, 42M float.
GeoVax has a 100% effective AIDS prevention vaccine.
GOVX brought in NLNKs Thomas Monath just as GOVX AIDS vax is starting another round of humna injection trials
Link:
https://finance.yahoo.com/news/geovax-announces-formation-scientific-advisory-140000691.html
NOTE: The person leading the development with Merck & NLNK is now a Director Of GeoVax. That is big.
"Thomas P. Monath, MD, (Chairman). Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck
GOVX: Ebola vax inventor for NLNX now with GOVX.
The news today is very strong. Some of the most important names in vaccine science now on Board of Directors
Link
:https://finance.yahoo.com/news/geovax-announces-formation-scientific-advisory-140000691.html
NOTE: The person leading the development with Merck & NLNK is now on the Board of Directors Of GeoVax. That is big.
"Thomas P. Monath, MD, (Chairman). Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck
GOVX @ .06 GeoVax News.
Link:
https://finance.yahoo.com/news/geovax-announces-formation-scientific-advisory-140000691.html
NOTE: The person leading the development with Merck & NLNK is now on the Board of Directors Of GeoVax. That is big.
"Thomas P. Monath, MD, (Chairman). Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck"
$CRTN @ .91: New CEO interview. ONLY profitable Nasdaq stock under $2.50.
Imo, they pre-announce strong Q4, 2016 Earning which ended on 12/31/16 & are due fist week in Feb.
Long January Effect month for CRTN.
Link:
http://ir.cartesian.com/phoenix.zh ..
$CRTN @ .91: New CEO interview. ONLY profitable Nasdaq stock under $2.50.
Imo, they pre-announce strong Q4, 2016 Earning which ended on 12/31/16 & are due fist week in Feb.
Long January Effect month for CRTN.
Link:
http://ir.cartesian.com/phoenix.zh ..
CRTN: New CEO interview: Big 2017.
LINK:
http://ir.cartesian.com/phoenix.zhtml?c=110509&p=irol-irhome
GOVX @ .06:Fed milestone $$ due for human AIDS vax trial start.
The pre-lim work started in last summer and GOVX got some cash to get the ball rolling.
The real money is due when the actual human vaccinations get underway in January.
The total is $7.8M...........GOVX total market cap now is $3.2M, with only 42M shares in the float
So, a serious payment have quite an impact.
Here is link to original news.
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
NOTE: GOVX also due Fed Zika funding from the hundreds of millions of $$ that Congress approved a few months ago. That money goes out in January , as well.
Zika funding grant was requested in April, 2016. GOVX will certainly get Zika funding, imo.
https://www.geovax.com/news-events/entry/2016/04/18/geovax-provides-update-on-zika-vaccine-program.html
GOVX @ .06: Fed milestone $$ due for human AIDS vax trial start.
The pre-lim work started in last summer and GOVX got some cash to get the ball rolling.
The real money is due when the actual human vaccinations get underway in January.
The total is $7.8M...........GOVX total market cap now is $3.2M, with only 42M shares in the float.
So, a serious payment have quite an impact.
Here is link to original news.
https://www.geovax.com/news-events/entry/2016/08/02/geovax-awarded-nih-contract-for-up-to-7-8-million-to-manufacture-hiv-vaccine-for-advanced-human-clinical-trials.html
NOTE: GOVX also due Fed Zika funding from the hundreds of millions of $$ that Congress approved a few months ago. That money goes out in January , as well.
Zika funding grant was requested in April, 2016. GOVX will certainly get Zika funding, imo.
https://www.geovax.com/news-events/entry/2016/04/18/geovax-provides-update-on-zika-vaccine-program.html
CRTN @ .92: Q4 ends 12/31. Earnings pre-announce next week?
Q4 news is due around 2/6/17.
The numbers are likely to be strong.
Imo, they make some news as quick as they can.
Likely a good idea to be holding CRTN when that news hits the wires.
NOTE: A close tomorrow over $1.00 would really kick off the January Effect for this play, putting them on target for being back in Nasdaq compliance @ the close on 1/12/17.
Link:
http://finance.yahoo.com/news/cartesian-reports-substantial-growth-number-170000231.html